News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Novartis Pharmaceuticals Corporation Drug Works For Parkinson’s Says FDA Staffer
May 16, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
An Alzheimer's drug made by Novartis Pharmaceuticals effectively treats dementia in patients with Parkinson's disease, but it is unclear if such mental impairments are two distinct conditions, U.S. Food and Drug Administration staff said on Tuesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Food and Drug Administration (FDA)
Novartis
MORE ON THIS TOPIC
PARTNERED
Where AI Adds Real Value in Clinical Development
May 12, 2025
·
7 min read
·
BioSpace Insights
Drug Development
Eroding Immunity: Vaccine Hesitancy and Cynicism With Paul Offit
May 8, 2025
·
1 min read
·
Lori Ellis
Gene therapy
CRISPR’s Casgevy on the Rise With More Gene Therapy Proof of Concept To Come in 2025
May 7, 2025
·
4 min read
·
Annalee Armstrong
Cancer
Summit’s Campaign To Conquer Keytruda Nears First Global Phase III Data
May 7, 2025
·
5 min read
·
Nick Paul Taylor